Estradiol Increases Risk of Topoisomerase $\alpha\beta$ -Mediated DNA Strand Breaks to Initiate Xp11.2 Translocation Renal Cell Carcinoma

Qiancheng Shi

Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

Ning Liu

Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

Lei Yang

Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu, China

Yi Chen

Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu 210093, China

Yanwen Lu

Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

Hongqian Guo

Department of Urology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

Xiaodong Han

Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu 210093, China

Dongmei Li

Immunology and Reproduction Biology Laboratory & State Key Laboratory of Analytical Chemistry for Life Science, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China; Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, Jiangsu 210093, China

Weidong Gan (✉ gwd@nju.edu.cn)

Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital <https://orcid.org/0000-0001-7144-3106>

Research

Keywords: renal cell carcinoma, Xp11.2, estradiol, estrogen receptor, topoisomerase, TFE3

Posted Date: June 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-554011/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Xp11.2 translocation renal cell carcinoma (tRCC) is defined by translocation of the transcription factor E3 (*TFE3*) gene located on chromosome Xp11.2. Due to the high incidence in women, 17 β -estradiol (E2) may be a factor influencing *TFE3* breaks, and the topoisomerase II (TOP2) poison is considered one of the important risk factors in mediating DNA breaks. In this study, we investigated the potential pathogenesis of Xp11.2 tRCC using the renal epithelial cell line HK-2.

Methods: Immunofluorescence assay was performed to analyze DNA breaks by quantifying phosphorylation of H2AX (γ H2AX), and the micronuclei (MN) assay was designed for monitoring chromosome breaks. The chromatin immunoprecipitation (CHIP) was used to detect whether proteins bound to specific DNA site, and the co-immunoprecipitation (Co-IP) was used to confirm whether proteins bound to other proteins. In some experiments, siRNA and shRNA were transfected to knockdown target genes.

Results: Our results demonstrated that DNA double-strand breaks were mediated by TOP2 β in HK-2 cells, and this process could be amplified through estrogen receptor α (ER α)-dependent pathway induced by E2. After performing translocation site analysis using target region sequencing data in two Xp11.2 tRCC cell lines and ten Xp11.2 tRCC patients, we confirmed that TOP2 β and ER α could both bind to *TFE3* translocation sites directly to mediate DNA breaks in a E2-dependent manner. However, TOP2 β and ER α were not observed to have direct interaction, indicating that their collaborative may be implemented in other ways. Besides, *TFE3* was found to be upregulated through NRF1 with increasing E2 concentration, which could increase the risk of *TFE3* breaks.

Conclusion: Our results indicate that E2 amplifies TOP2 β -mediated *TFE3* breaks by ER α -dependent pathway, and E2 upregulates *TFE3* by NRF1 to increase the risk of *TFE3* breaks. This suggests that E2 is an important pathogenic factor for Xp11.2 tRCC pathogenesis.

Background

Xp11.2 translocation renal cell carcinoma (tRCC), first reported in 1988, is characterized by a pathognomonic chromosomal translocation of transcription factor E3 (*TFE3*), which causes fusion of the *TFE3* gene with a variety of partner genes [1, 2]. Children and young adults are most often affected, for 46.7% of paediatric RCCs and 15% of young adult (aged < 45 years) RCCs are Xp11.2 tRCC, and the peak age of onset is 20–29 years [3–5]. Due to its aggressiveness, Xp11.2 tRCC is characterized by poor prognosis with local invasive and distant metastases [6–9], and the high prevalence of young adults increased the medical care related to complications of this disease in recent years. Another important feature of Xp11.2 tRCC is the female predominance. The female/male ratio of Xp11.2 tRCC is 1.68 to 2 [10, 11], which is totally different from common RCCs [12]. Considering age- and sex-specific factors of this type of RCC, we suspect that estrogen may play an important role in the pathogenesis of Xp11.2 tRCC.

The topoisomerase II (TOP2) poison has been reported to be a causal agent of this type of RCC, for patients could have a history of TOP2 poisons (etoposide or doxorubicin) use before diagnosed with Xp11.2 tRCC [13–15]. These drugs are used in the treatment of a variety of cancers as a broad class of chemotherapeutic agents [16]. The role of TOP2-mediated DNA double-strand breaks in translocation tumors especially MLL leukemia has been widely reported [17, 18]. However, whether the specific *TFE3* gene breaks in Xp11.2 tRCC are produced via TOP2-mediated DNA double-strand breaks is still unclear. Exploring the TOP2-mediated DNA double-strand breaks at *TFE3* translocation sites has important implications in understanding the pathogenesis of Xp11.2 tRCC.

Since 17 β -estradiol (E2) and estrogen receptor (ER)-mediated DNA breaks have been reported [19, 20], we consider that E2 and ER may induce *TFE3* breaks through TOP2-mediated DNA double-strand breaks in Xp11.2 tRCC. Thus, this study was designed to confirm the role of TOP2-mediated DNA double-strand breaks in *TFE3* translocation sites of Xp11.2 tRCC, and the regulatory functions of E2 and ER in this process.

Materials And Methods

Cell culture

HK-2 cells were obtained from ATCC (ATCC® CRL-2190™), and then authenticated by STR profiling at Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. These HK-2 cells were cultured in base medium provided by Invitrogen (GIBCO) supplemented with 0.05 mg/ml bovine pituitary extract (BPE) and 5 ng/ml human recombinant epidermal growth factor (EGF) in 5% CO₂ at 37°C. For etoposide stimulation, HK-2 cells were plated in base medium with 0.05 mg/ml BPE and 5 ng/ml EGF for a minimum of 16 h before being washed 3 times in 1x PBS. The same medium was then added for 1 h prior to the addition of etoposide dissolved in DMSO or the vehicle control (100% DMSO). For estrogen stimulation, HK-2 cells were pre-processed using the same approach as mentioned earlier, and the same medium with E2 dissolved in DMSO or the vehicle control were then added for 24 h or 48 h. UOK109 and UOK120 cells were gifts of Dr. W. Marston Linehan, National Cancer Institute, Bethesda, MD. The UOK109 and UOK120 cell lines were derived from primary RCC as described [21], and were derived from tumors arising in a 30- and a 39-year-old male, respectively. These UOK109 and UOK120 cells were cultured in DMEM (GIBCO) supplemented with 10% FBS in 5% CO₂ at 37°C.

Antibodies, plasmids, reagents, and primers

Antibodies to P-H2AX (Cell Signaling, 80312S), TOP2 β (Abcam, ab72334), CTCF (Abcam, ab128873), ER- α (Cell Signaling, 8644S), and Alexa Fluor Plus 488 (Invitrogen, A32723) were used. Two siRNA were used to deplete *TOP2A* and *TOP2B* separately, and NC siRNA was used for negative control. Three shRNA were used to knockdown *ESR1*, *ESR2* and *NRF1* separately, and NC shRNA was used for negative control. The siRNA sequences and shRNA sequences can be found in the supplementary materials [see Additional file 1]. All siRNA transfections were performed using Lipofectamine 2000™ (Thermo Fisher, 11668019)

according to the manufacturer's protocol and 20 nM siRNA. All lentiviral vectors expressing the scramble shRNA transfections were performed using polybrene (Sigma-Aldrich, TR-1003). Etoposide (Sigma-Aldrich, E1383) and E2 (Sigma-Aldrich, E8875) was dissolved in DMSO (Sigma-Aldrich, D2650). All primers and primer sequences can be found in the supplementary materials [see Additional file 1].

Relative quantitative real-time polymerase chain reaction

The action mixture consisted of 10 µl SYBR Green (Vazyme, Nanjing, Q711-02), 10 µM each primer, 1 µl cDNA. PCR amplifications were performed on the 7300 real-time PCR system (Applied Biosystems, CA, US). The relative mRNA expression level was calculated by the comparative $2^{-\Delta\Delta C_t}$ method and normalized against ACTB mRNA. For reverse transcription-PCR analysis, amplification was done for 33 cycles, each with denaturation at 95°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s.

Micronuclei assays

Cytochalasin B (MCE, HY-16928) and Acridine Orange (Sigma-Aldrich, A6014) were used for micronuclei assays as reported in literature [22].

Fluorescence *in-situ* hybridization (FISH)

FISH was performed using FISH Tag DNA Green Kit (Thermo Fisher, F32947).

BAC clones CTD-2516D6 (*TFE3*-5'), CTD-2522M13 (*TFE3*-5'), RP11-416814 (*TFE3*-5'), CTD-2312C1 (*TFE3*-3'), CTD-2248C21 (*TFE3*-3'), RP11-959H17 (*TFE3*-3') were selected from The UCSC Genome Browser (<http://genome.ucsc.edu>). Probes were labeled with FITC (all 5' probes) and TexasRed (all 3' probes) conjugated dUTP (C7604, C7631, Invitrogen).

Chromatin immunoprecipitation (ChIP)

Chromatin immunoprecipitation was performed using Pierce Magnetic ChIP Kit (Thermo Fisher, 26157). The HK-2 cells were crosslinked using formaldehyde with a final concentration of 1%, and the number of cells required 2×10^6 .

Co-immunoprecipitation (Co-IP)

Co-IP was performed using Pierce Co-Immunoprecipitation Kit (Thermo Fisher, 26149). For each IP, 8 µg antibody (ER-α (Cell Signaling, 8644S)) was added.

Results

E2 induces *TFE3* breaks in HK-2 cells

Considering the potential oncogenic role of E2 in the pathogenesis of Xp11.2 tRCC, we assessed the ability of E2 to induce DNA breaks. The renal epithelial cell line HK-2 was treated with E2 at a

concentration of 10 nM, and the histone H2AX phosphorylation was used as an indicator for reflecting DNA double-strand breaks. When using immunofluorescent staining to detect phosphorylated H2AX (γ -H2AX) foci, E2 induced remarkably breaks more than control group after 48h (Fig. 1A and B). To directly assess the role of E2 in generating breaks at the *TFE3* locus, we used DNA-FISH with a “break-apart” rearrangement probe to quantify *TFE3* breaks (Fig. 1C and D). E2 could induce *TFE3* breaks significantly after 48h at the concentration of 10 nM in HK-2 cells (Fig. 1E). The results confirm the role of E2 in *TFE3* breaks.

TOP2 β mediates DNA double-strand breaks

To ascertain the role of TOP2-mediated DNA cleavage in renal carcinogenesis with chromosomal translocation, HK-2 cells were treated with the TOP2 poison etoposide at a concentration of 100 μ M for a short time period (1 h) (Fig. S1A). Results showed that etoposide induced remarkably breaks more than control group (Fig. 2A and B). To determine which of the two TOP2 affected the etoposide-induced DNA damage across the genome, HK-2 cells were transfected with negative control siRNA (NC), siRNA against *TOP2A* (siTOP2A), or siRNA against *TOP2B* (siTOP2B) (Fig. S1C). The immunofluorescence analysis showed similar results, DNA breaks of each group were extensively increased after etoposide treatment, but only *TOP2B* knockdown significantly decreased the γ -H2AX foci (Fig. 2C and D), indicating that *TOP2B* knockdown decreased DNA breaks. To verify the contribution made by TOP2 to etoposide-induced genotoxicity at the chromatin level, we next carried out micronuclei (MN) assays (Fig. S1D). The *TOP2A* knockdown group behaved in the same way as control group, whereas in *TOP2B* knockdown group there was a significant decrease in the MN frequency of etoposide-treated cells (Fig. 2E). These results show that TOP2 β mediates DNA double-strand breaks in HK-2 cells, supporting the role for TOP2 β in the genotoxic effects of etoposide.

TOP2 β mediates *TFE3* breaks directly

To further clarify the specific mechanism of *TFE3* breaks in Xp11.2 tRCC, we used DNA-FISH with a “break-apart” rearrangement probe as above described. Results showed that etoposide induced approximately twentyfold breaks at the *TFE3* locus in HK-2 cells, and breaks in the same position was substantially reduced in *TOP2B* knockdown group (Fig. 3A and B). Subsequently, DNA sequences of the translocation site were analyzed via target region sequencing in two Xp11.2 tRCC cell lines, UOK109 and UOK120 (Fig. 3C and S2). We used ChIP-qPCR to determine the distribution of TOP2 β over the translocation sites in UOK109 and UOK120 cells, respectively. The results of sampling multiple translocation sites in Xp11.2 tRCC revealed the presence of TOP2 β in chromatin in most of the positions sampled (Fig. 3D and E). The same sites were analyzed in cells treated with 100 μ M etoposide for 60 min, which resulted in a large increase in stabilized covalent TOP2 β DNA complexes. Because CTCF has been reported to bind at anchors of chromatin loops, where requires TOP2 for the initiation of transcription [23], we measured CTCF binding in the same way (Fig. 3F and G). Sampling CTCF binding in the same positions confirmed the presence of a CTCF binding. This is further proof that the *TFE3* breaks in Xp11.2 tRCC are a result of TOP2 β -mediated DNA breaks.

E2 induces *TFE3* breaks through ER α -dependent pathway

To assess whether the effects of E2 are mediated via ER, we constructed shRNA-lentivirus to knockdown *ESR1* or *ESR2* expression in HK-2 cells (Fig. S1G), and repeated the above described experiment using *ESR1* and *ESR2* knockdown cells. Quantification of γ -H2AX showed that the increase of DNA breaks induced by E2 was disappeared after knockdown of *ESR1* (Fig. 4A and B). Similar results were also observed in subsequent MN assays (Fig. 4C). In order to investigate whether ER α were associated with *TFE3* breaks in Xp11.2 tRCC, we used DNA-FISH with a “break-apart” rearrangement probe as above described. Results revealed that E2-induced *TFE3* breaks were markedly attenuated in *ESR1* knockdown cells (Fig. 4D). The results show that E2 induces *TFE3* breaks through ER α -dependent pathway.

To verify this, ChIP-qPCR experiments were performed in HK-2 cells with the specific anti-ER α antibodies validated by ChIP-qPCR. The results showed that ER α bound to multiple sites near the translocation site of *TFE3* and other partner genes (*NONO* and *PRCC*) (Fig. 4E and F). After induction with E2 (10 nM), a substantial increase in binding intensities of ER α was observed at these sites. These results reveal that ER α induce *TFE3* breaks directly.

TOP2 β and ER α have a combined effect in mediating DNA breaks

To determine the association between E2-induced DNA breaks and TOP2 β -mediated DNA breaks, HK-2 cells were treated with a concentration gradient of etoposide (0, 1, 2, 5, 10, 20, 50, and 100 μ M) to determine the appropriate concentration which could induce similar numbers of breaks to 10 nM E2 treatment (Fig. 5A and B). The results showed that etoposide treatment of 0 to 5 μ M could not induce a significant DNA breaks in HK-2 cells, and DNA breaks were significantly increased from the concentration of 10 μ M. At the same time, the 10 μ M etoposide treatment group showed similar DNA breaks to that of the 10 nM E2 group ($p > 0.05$). So, the concentration of 10 μ M etoposide was used in the follow-up studies to explore the combined effects of these two drugs.

The *TOP2B* knockdown cells and control cells were treated with 0.1% DMSO (solvent-only control), 10 nM E2, 10 μ M etoposide or a combination of the two drugs, respectively. Quantification of γ -H2AX showed that DNA breaks were significantly reduced in *TOP2B* knockdown cells whether treated with E2, etoposide or a combination of the two drugs (Fig. 5C and D). Similarly, we repeated the similar experiment using *ESR1* knockdown HK-2 cells. Results showed that DNA breaks were also significantly reduced in *ESR1* knockdown cells whether treated with E2, etoposide or a combination of the two drugs (Fig. 5E and F). Taken together, these results indicating that TOP2 β and ER α play a synergistic role in the process of DNA breaks induced by E2 or etoposide.

Based on this finding, we speculated that E2 might function by modulating the interaction between ER α and TOP2 β . We then performed Co-IP experiments, proteins directly bound to ER α were detected by western blot with anti-TOP2 β antibodies. Unfortunately, no binding signal of TOP2 β was observed in HK-2 cells with or without E2 treatment (Fig.5G). Another explanation may be that the direct binding of ER α to

TFE3 sequence affects the structural, and possibly the functional, properties of TOP2 β , resulting in the site-specific break in the translocation site of *TFE3*.

Further validation in ten Xp11.2 tRCC patients

To further verify the conclusions drawn above, we used target region sequencing to analyze the DNA sequences of the translocation site in ten Xp11.2 tRCC patients [see Additional file 1]. And primers were designed within 100bp before or after the translocation site, if possible. We then used ChIP-qPCR to determine the distribution of TOP2 β and ER α over the translocation sites in ten Xp11.2 tRCC patients, using HK-2 cells with or without etoposide or E2 treatment respectively. The results showed that TOP2 β and ER α extensively bound to multiple sites near the translocation site of *TFE3* and other partner genes (*NONO*, *PRCC*, *SFPQ*, *ASPSCR1* and *MED15*) (Fig. 6A-D). This is further proof that the *TFE3* breaks in Xp11.2 tRCC are a result of ER α and TOP2 β -mediated DNA breaks.

E2 increases the risk of *TFE3* breaks through NRF1 pathway

To investigate whether E2 can regulated *TFE3* expression, we tested renal *TFE3* mRNA level and serum E2 concentration in BalbC mice aged 4-10 weeks. Results showed that *TFE3* expression was significantly associated with E2 concentration (Fig. 7A). We further observed that dose-dependent significant increases in *TFE3* and *ESR1* with increasing E2 concentration in HK-2 cells (Fig. 7B and C). We considered whether activation of *TFE3* expression by ER α -dependent pathway could increase the risk of *TFE3* breaks. However, there was no ER α -binding site in the promoter region of *TFE3*, predicted by using the online website JASPAR (<http://jaspar.genereg.net/>). To identify putative transcription factors that can bind to the promoter region of *TFE3*, we systematically searched databases of known human transcription factors [see Additional file 2]. Results are sorted by best relative score. Apart from a broad-spectrum binding protein to zinc finger domain, ZNF263, the highest score was given to NRF1. Since the ability of E2 to regulate *NRF1* expression has been widely confirmed by previous researches [24], we then examined whether NRF1 was involved in *TFE3* expression induced by E2. We found that *TFE3* expression was drastically reduced following *NRF1* knockdown, and the dose-dependent increases was also disappeared with increasing E2 concentration (Fig. 7D, E and S1D). Together, the results show that E2 upregulates *TFE3* expression by enhancing its transcriptional activity through NRF1 pathway and consequently increases the risk of *TFE3* breaks.

Discussion

Since Xp11.2 tRCC has been formally described as a distinct clinicopathologic entity in 2001, there has been a lot of research attention given to the function of TFE3 fusion proteins [25–27]. However, few studies have investigated the pathogenesis of Xp11.2 tRCC. Our study proposed that physiological concentrations of E2 could induce *TFE3* breaks in Xp11.2 tRCC, which explained the high morbidity in women. In this study, we confirmed that *TFE3* breaks were mediated by TOP2 β , which process could be amplified through ER α -dependent pathway induced by E2. Although TOP2 β and ER α could both bind to *TFE3* translocation sites directly to mediate DNA breaks, no direct interaction was observed, indicating

that their collaborative may be implemented in other ways. Besides, *TFE3* was found to be upregulated through NRF1 with increasing E2 concentration, which could increase the risk of *TFE3* breaks.

Different from etoposide with rapid onset, E2 require an extended period (48 h) of treatment to induce *TFE3* breaks. On the one hand, this may because the indirectly affected of ER α -mediated DNA breaks is less prominently than acting directly on TOP2 β . On the other hand, E2 induced increase in transcriptional activity of *TFE3* requires the expression of *NRF1*, resulting in a delayed *TFE3* breaks. This may explain the reason why the peak age of onset is 20–29 years instead of the early pubertal stages suffering initial exposure with high concentrations of E2 [5].

Several studies reported about the function of sex hormone in TOP2 β -mediated DNA breaks. Michael et al. [28] find that TOP2 β mediates DNA breaks through directly binding to androgen receptor at the position of androgen receptor downstream target gene promoters. We pre-retrieved and analyzed the corresponding ChIP-seq data through the Cistrome DB database (<http://cistrome.org/>). The results showed that TOP2 β and CTCF were both found to bind to the *TFE3* gene and partner genes we were concerned about (PRCC, SFPQ, ASPSCR1, NONO, MED-15) [see Additional file 3]. Since TOP2 β has been proved to mediate DNA breaks [29], we used TOP2 β ChIP to demonstrate the binding of TOP2 β at the translocation sites to prove that the *TFE3* gene could break at the translocation sites through TOP2 β -mediated DNA breaks. And we used *TFE3* break-apart FISH to detect *TFE3* breaks. The further ER α ChIP was also used to explore the potential effects of ER α on TOP2 β at the translocation site. However, our study failed to find the direct bindings of ER α and TOP2 β , we proposed that ER α and TOP2 β could be co-recruited to translocation sites in the intron regions rather than only in the promoter regions. Based on the study that TOP2 cleaves DNA double strands to results in TOP2 cleavage complex (TOP2cc) through a transesterification reaction [30], we put forward hypothesis that, in a narrow spatial chromatin region, the binding of ER α with DNA sequence near the breaking site may have spatial-dependent harms on the biological functions of TOP2cc, making TOP2cc fall off from DNA strands, and finally resulting in DNA breaks. Thus, further research should be done to prove this hypothesis. And we found evidence for enrichment of CTCF at *TFE3* translocation sites, implying that *TFE3* translocation sites may located in anchors of chromatin loops [29]. This also explains why *TFE3* translocation sites are more located in the intron 3–4 and intron 5–6, based on the DNA fragility caused by spatial chromosome folding [31, 32].

Studies confirm that TOP2-mediated DNA breaks acts primarily through transcription-dependent processes [30, 33], suggesting a higher risk of DNA breaks in highly transcribed genes. And the effect of estrogen on the occurrence of tumors has been widely concerned. Previous animal experiments have confirmed that estrogen can induce the occurrence of hamster kidney tumors [34]. Estrogen is an important reproductive endocrine hormone, which regulates the expression of thousands of genes by combining with ER. ER α expression predominant in uterus, pituitary, kidney, and adrenal gland and ER β expression predominant in ovarian granulosa cells, prostate, bladder, and lung [35]. Among all genes regulated by estrogen, the number of genes expressed by the kidney ranks third, and even more than that of ovarian granulosa cells [36]. Therefore, we considered that E2 could upregulate *TFE3* expression by enhancing its transcriptional activity through NRF1 pathway, and consequently increase the risk of *TFE3*

breaks. And finally, we found that E2 regulated *TFE3* transcription via NRF-1. As the publication work of the detailed research on the regulation of *TFE3* transcription by NRF1 is in progress, only a brief verification was provided in this study. On the other hand, when reviewing the transcript levels of fusion partners in Xp11.2 tRCC, we found that some of them were housekeeping genes with high transcriptional activity [37], such as *NONO* and *CLTC*. This caused that these fusion partners are more accessible to face DNA breaks and chromosome translocations, which reflected that the seemingly random chromosome translocations might have an inevitable reason.

Besides, based on the specificity of the *TFE3* gene, studies have confirmed that TFE3 can be activated during DNA damage, and play an important role by directly regulating p53, causing cell cycle arrest or apoptosis [38]. Which means the changes in TFE3 protein function by the translocation at Xp11.2 can further aggravate the consequences of DNA damage, and thus played an important role in this process of tumorigenesis.

In a sense, this study offers a method for predicting translocation sites in Xp11.2 tRCC. Our data indicated that ER α and TOP2 β were co-recruited to translocation sites not only in *TFE3* gene, but also in fusion partner genes. Conversely, we can explore new fusion partners or translocation sequences by analyzing the intersection between ER α -bound sequence and TOP2 β -bound sequence. However, the generation of tRCC involves not only the occurrence of DNA breaks, but also obstacles to the double-strand repair mechanism. Considering that this was a multi-factor participation process, other factors such as gene mutation, sudden changes in hormone levels were also play an important role. The pathogenesis of tRCC cannot not be predicted by ER α and TOP2 β alone. Through further studies of potential translocation sequence in fusion partners, the rules governing fusion partner choice in Xp11.2 tRCC may be delineated.

Conclusions

This study indicates that E2 amplifies TOP2 β -mediated *TFE3* breaks by ER α -dependent pathway, and E2 upregulates *TFE3* by NRF1 to increase the risk of *TFE3* breaks. Which suggests that E2 is an important pathogenic factor for Xp11.2 tRCC pathogenesis.

Abbreviations

tRCC: translocation renal cell carcinoma

TFE3: transcription factor E3

TOP2: topoisomerase

E2: 17 β -estradiol

ER: estrogen receptor

BPE: bovine pituitary extract

EGF: epidermal growth factor

FISH: fluorescence in-situ hybridization

ChIP: chromatin immunoprecipitation

Co-IP: co-immunoprecipitation

γ -H2AX: phosphorylated H2AX

MN: micronuclei

NRF1: nuclear respiratory factor 1

TOP2cc: TOP2 cleavage complex

Declarations

Ethical Approval and Consent to participate

This study was approved by the Ethics Committee of Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School.

Consent for publication

This study was completed and consented to be published.

Availability of supporting data

Supporting data were available to all researchers.

Competing interests

No conflict of interest.

Funding

This research was supported by the State Key Laboratory of Analytical Chemistry for Life Science (5431ZZXM2004), and Beijing Ronghe Medical Development Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' contributions

Conception and design: Qiancheng Shi

Acquisition of data: Qiancheng Shi

Analysis and interpretation of data: Qiancheng Shi

Drafting of the manuscript: Qiancheng Shi

Critical revision of the manuscript for important intellectual content: Qiancheng Shi, Ning Liu, Dongmei Li

Statistical analysis: Qiancheng Shi

Obtaining funding: Dongmei Li, Weidong Gan

Administrative, technical, or material support: Ning Liu, Lei Yang, Yi Chen, Yanwen Lu, Hongqian Guo, Xiaodong Han, Dongmei Li, Weidong Gan

All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors' information

Qiancheng Shi, 321 Zhongshan Road, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China. Email: sqc@smail.nju.edu.cn.

Ning Liu, 321 Zhongshan Road, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China. Email: LNjubg@163.com.

Lei Yang, 22 Hankou Road, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China. Email: younglei123@163.com.

Yi Chen, 22 Hankou Road, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China. Email: DG20350032@smail.nju.edu.cn.

Yanwen Lu, 321 Zhongshan Road, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China. Email: DG20350068@smail.nju.edu.cn.

Hongqian Guo, 321 Zhongshan Road, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China. Email: dr.guohongqian@gmail.com.

Xiaodong Han, 22 Hankou Road, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China. Email: hanxd@nju.edu.cn.

Dongmei Li, 22 Hankou Road, Medical School, Nanjing University, Nanjing, Jiangsu 210093, China. Email: lidm@nju.edu.cn.

References

1. de Jong B, Oosterhuis JW, Idenburg VJ, Castedo SM, Dam A, Mensink HJ. Cytogenetics of 12 cases of renal adenocarcinoma. *Cancer genetics and cytogenetics*. 1988;30(1):53-61.
2. Argani P. MiT family translocation renal cell carcinoma. *Seminars in diagnostic pathology*. 2015;32(2):103-13.
3. Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. *Cancer*. 2015;121(14):2457-64.
4. Kuroda N, Mikami S, Pan CC, Cohen RJ, Hes O, Michal M, Nagashima Y, Tanaka Y, Inoue K, Shuin T, Lee GH. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. *Histology and histopathology*. 2012;27(2):133-40.
5. Calìo A, Segala D, Munari E, Brunelli M, Martignoni G. MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. *Cancers*. 2019;11(8).
6. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE, Ladanyi M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. *The American journal of surgical pathology*. 2007;31(8):1149-60.
7. Mir MC, Trilla E, de Torres IM, Panizo A, Zlotta AR, Van Rhijn B, Morote J. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. *BJU international*. 2011;108(2 Pt 2):E71-6.
8. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, Epstein JI, Netto GJ, Argani P. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2014;27(6):875-86.
9. He J, Chen X, Gan W, Zhu B, Fan X, Guo H, Jia R. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review. *Future oncology (London, England)*. 2015;11(24):3243-52.
10. Cheng X, Gan W, Zhang G, Li X, Guo H. Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies. *BMC urology*. 2016;16(1):40.
11. Zhuang W, Liu N, Guo H, Zhang C, Gan W. Gender difference analysis of Xp11.2 translocation renal cell carcinomas's attack rate: a meta-analysis and systematic review. *BMC urology*. 2020;20(1):130.
12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA: a cancer journal for clinicians*. 2020;70(1):7-30.

13. Argani P, Laé M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M. Translocation carcinomas of the kidney after chemotherapy in childhood. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2006;24(10):1529-34.
14. Al-Mashaikhi N, Yang J, Terry J, Barr R. Renal cell carcinoma with Xp 11.2 translocation as a second tumor in a long-term survivor of advanced neuroblastoma. *Pediatric hematology and oncology*. 2015;32(3):215-22.
15. Rais-Bahrami S, Drabick JJ, De Marzo AM, Hicks J, Ho C, Caroe AE, Argani P. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. *Urology*. 2007;70(1):178.e3-6.
16. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. *Nature reviews Cancer*. 2009;9(5):338-50.
17. Mirault ME, Boucher P, Tremblay A. Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot. *American journal of human genetics*. 2006;79(5):779-91.
18. Cowell IG, Sondka Z, Smith K, Lee KC, Manville CM, Sidorczuk-Lesthurge M, Rance HA, Padget K, Jackson GH, Adachi N, Austin CA. Model for MLL translocations in therapy-related leukemia involving topoisomerase II β -mediated DNA strand breaks and gene proximity. *Proceedings of the National Academy of Sciences of the United States of America*. 2012;109(23):8989-94.
19. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase II β -mediated dsDNA break required for regulated transcription. *Science (New York, NY)*. 2006;312(5781):1798-802.
20. Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, Nussenzweig A, Takeda S. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115(45):E10642-e51.
21. Anglard P, Trahan E, Liu S, Latif F, Merino MJ, Lerman MI, Zbar B, Linehan WM. Molecular and cellular characterization of human renal cell carcinoma cell lines. *Cancer research*. 1992;52(2):348-56.
22. Fenech M. The in vitro micronucleus technique. *Mutation research*. 2000;455(1-2):81-95.
23. Uusküla-Reimand L, Hou H, Samavarchi-Tehrani P, Rudan MV, Liang M, Medina-Rivera A, Mohammed H, Schmidt D, Schwalie P, Young EJ, Reimand J, Hadjur S, Gingras AC, Wilson MD. Topoisomerase II β interacts with cohesin and CTCF at topological domain borders. *Genome biology*. 2016;17(1):182.
24. Das JK, Felty Q, Poppiti R, Jackson RM, Roy D. Nuclear Respiratory Factor 1 Acting as an Oncoprotein Drives Estrogen-Induced Breast Carcinogenesis. *Cells*. 2018;7(12).
25. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA, Ladanyi M. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal

- cell carcinomas of children and adolescents. *The American journal of pathology*. 2001;159(1):179-92.
26. Yin X, Wang B, Gan W, Zhuang W, Xiang Z, Han X, Li D. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas. *J Exp Clin Cancer Res*. 2019;38(1):119-.
 27. Wang B, Yin X, Gan W, Pan F, Li S, Xiang Z, Han X, Li D. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma. *Autophagy*. 2020:1-19.
 28. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. *Nat Genet*. 2010;42(8):668-75.
 29. Gothe HJ, Bouwman BAM, Gusmao EG, Piccinno R, Petrosino G, Sayols S, Drechsel O, Minneker V, Josipovic N, Mizi A, Nielsen CF, Wagner EM, Takeda S, Sasanuma H, Hudson DF, Kindler T, Baranello L, Papantonis A, Crosetto N, Roukos V. Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations. *Molecular cell*. 2019;75(2):267-83.e12.
 30. Ashour ME, Atteya R, El-Khamisy SF. Topoisomerase-mediated chromosomal break repair: an emerging player in many games. *Nature Reviews Cancer*. 2015;15(3):137-51.
 31. Tretiakova MS, Wang W, Wu Y, Tykodi SS, True L, Liu YJ. Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features. *Genes, chromosomes & cancer*. 2019.
 32. Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, Aulmann S. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. 2012;25(2):308-15.
 33. Canela A, Maman Y, Huang SYN, Wutz G, Nussenzweig A. Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity. *Molecular cell*. 2019;75(2):252-66.e8.
 34. Liehr JG, Roy D. Free radical generation by redox cycling of estrogens. *Free radical biology & medicine*. 1990;8(4):415-23.
 35. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. *Endocrinology*. 1997;138(3):863-70.
 36. Jelinsky SA, Harris HA, Brown EL, Flanagan K, Zhang X, Tunkey C, et al. Global transcription profiling of estrogen activity: estrogen receptor alpha regulates gene expression in the kidney. *Endocrinology*. 2003;144(2):701-10.
 37. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, Misra J, Dillon W, Lee KF, Clark KE, Haverty P, Weng Z, Mutter GL, Frosch MP, MacDonald ME, Milford EL, Crum CP, Bueno R, Pratt RE,

- Mahadevappa M, Warrington JA, Stephanopoulos G, Stephanopoulos G, Gullans SR. A compendium of gene expression in normal human tissues. *Physiological genomics*. 2001;7(2):97-104.
38. Brady OA, Jeong E, Martina JA, Pirooznia M, Tunc I, Puertollano R. The transcription factors TFE3 and TFEB amplify p53 dependent transcriptional programs in response to DNA damage. *eLife*. 2018;7.

Figures

Figure 1

17 β -estradiol (E2)-induced DNA breaks and TFE3 breaks analysis. (A) Phosphorylation of H2AX (γ H2AX) foci detected in HK-2 cells under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 24 h or 48 h. (B) Quantification of the γ H2AX foci in E2-treated cells as in panel (A). (C) Pattern diagram of TFE3 break-apart rearrangement probe. (D) Examples of fusion and break-apart signal using TFE3 break-apart breaksfluorescence in situ hybridization (FISH) probe. (E) Quantification of the TFE3 break-apart signals

in HK-2 cells under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. Error bars indicate 95% confidence intervals (** $p < 0.01$, *** $p < 0.001$).

Figure 2

Etoposide-induced topoisomerase α (TOP2)-mediated DNA breaks and chromosomal breaks. (A) γ H2AX foci detected in HK-2 cells under 0.1% DMSO (solvent-only control) or 100 μ M etoposide treatment for 1 h. (B) Quantification of the γ H2AX foci in etoposide-treated cells as in panel (A). (C) γ H2AX foci

detected in HK-2 cells transfected with negative control siRNA (NC), siRNA against TOP2A (siTOP2A), or siRNA against TOP2B (siTOP2B) under 0.1% DMSO (solvent-only control) or 100 μ M etoposide treatment for 1 h. (D) Quantification of the γ H2AX foci in etoposide-treated cells as in panel (C). (E) Quantification of the micronuclei (MNs) in etoposide-treated cells as in panel (C). Error bars indicate 95% confidence intervals (***) $p < 0.001$).

Figure 3

Etoposide-induced TOP2-mediated TFE3 breaks in Xp11.2 translocation renal cell carcinoma (tRCC) translocation sites. (A) Quantification of the TFE3 break-apart signals in HK-2 cells under 0.1% DMSO (solvent-only control) or 100 μ M etoposide treatment for 1 h. (B) Quantification of the TFE3 break-apart signals in HK-2 cells transfected with NC or siTOP2B under 0.1% DMSO (solvent-only control) or 100 μ M etoposide treatment for 1 h. (C) Ideograms of the translocation fragments of two Xp11.2 tRCC cell lines, UOK109 and UOK120. (D and E) Statistics of TOP2 β chromatin immunoprecipitation (ChIP)-qPCR results performed using the primers near the translocation sites as in panel (C) in HK-2 cells under 0.1% DMSO (solvent-only control) or 100 μ M etoposide treatment for 1 h. (F and G) Statistics of CTCF ChIP-qPCR results performed using the same primers as in panel (D and E) in HK-2 cells. ChIP-qPCR was normalized to Input DNA, experiments were repeated three times and data shown are means $\pm$ SD. Error bars indicate 95% confidence intervals (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Figure 4

E2 induced-TFE3 breaks through ER α -dependent pathway. (A) γ H2AX foci detected in HK-2 cells transfected with negative control shRNA (NC), shRNA against ESR1 (shESR1), or shRNA against ESR2 (shESR2) under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. (B) Quantification of the γ H2AX foci in E2-treated cells as in panel (A). (C) Quantification of the MNs in E2-treated cells as in panel (A). (D) Quantification of the TFE3 break-apart signals in HK-2 cells transfected with NC or shESR1

under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. (E and F) Statistics of TOP2β ChIP-qPCR results performed using the primers near the translocation sites in HK-2 cells under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. ChIP-qPCR was normalized to Input DNA, experiments were repeated three times and data shown are means ± SD. Error bars indicate 95% confidence intervals (** p < 0.01, *** p < 0.001).

Figure 5

Combined effect of TOP2 β and ER α in mediating DNA breaks. (A) γ H2AX focus detected in HK-2 cells under 10 nM E2 treatment for 48 h or a concentration gradient of etoposide (0, 1, 2, 5, 10, 20, 50, 100 μ M) for 1 h. (B) Quantification of the γ H2AX focus in cells as in panel (A). (C and D) γ H2AX focus detected in HK-2 cells transfected with negative control siRNA (NC), siRNA against TOP2A (siTOP2A), or siRNA against TOP2B (siTOP2B) under 0.1% DMSO (solvent-only control), 10 nM E2, 10 μ M etoposide or a combination of the two drugs and their quantification. (E and F) γ H2AX focus detected in HK-2 cells transfected with negative control shRNA (NC), shRNA against ESR1 (shESR1), or shRNA against ESR2 (shESR2) under 0.1% DMSO (solvent-only control), 10 nM E2, 10 μ M etoposide or a combination of the two drugs and their quantification. (G) Western blot of ER α co-immunoprecipitation (Co-IP) detected with anti-Top2 β antibodies. Error bars indicate 95% confidence intervals (***) $p < 0.001$.

Figure 6

E2-induced ERα and TOP2β-dependent TFE3 breaks in translocation sites of ten Xp11.2 tRCC patients. (A) Statistics of TOP2β ChIP-qPCR results performed using primers designed for partner genes (NONO, PRCC, SFPQ, ASPSCR1 and MED15) in ten Xp11.2 tRCC patients in HK-2 cells under 0.1% DMSO (solvent-only control) or 100 μM etoposide treatment for 1 h. (B) Statistics of TOP2β ChIP-qPCR results performed using primers designed for TFE3 in ten Xp11.2 tRCC patients in HK-2 cells under 0.1% DMSO (solvent-

only control) or 100 μ M etoposide treatment for 1 h. (C) Statistics of ER α ChIP-qPCR results performed using the same primers as in panel (A) in HK-2 cells under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. (D) Statistics of ER α ChIP-qPCR results performed using the same primers as in panel (B) in HK-2 cells under 0.1% DMSO (solvent-only control) or 10 nM E2 treatment for 48 h. ChIP-qPCR was normalized to Input DNA, experiments were repeated three times and data shown are means $\pm$ SD. Error bars indicate 95% confidence intervals (** $p < 0.001$).

Figure 7

E2-induced NRF1-dependent TFE3 expressions. (A) Correlation analysis of TFE3 mRNA level and serum E2 concentration in BalbC mice aged 4-10 weeks. (B) Statistics of TFE3 qPCR results in HK-2 cells under 0.1% DMSO (solvent-only control), 1 nM, 5 nM, 10 nM, 15 nM or 20 nM E2 treatment for 48 h. (C) Statistics of ESR1 qPCR results in E2-treated cells as in panel (B). (D) Statistics of TFE3 qPCR results in HK-2 cells transfected with negative control shRNA (NC) or shRNA against NRF1 (shNRF1) under the same treatment as in panel (B). (E) Statistics of NRF1 qPCR results in E2-treated cells as in panel (D). Error bars indicate 95% confidence intervals (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigS1.tif](#)
- [Additionalfile1.docx](#)
- [Additionalfile2.xlsx](#)
- [Additionalfile3.docx](#)